313 related articles for article (PubMed ID: 34976809)
1. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.
Xu J; Lin H; Wu G; Zhu M; Li M
Front Oncol; 2021; 11():760971. PubMed ID: 34976809
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
4. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
7. IL-6 upregulates the expression of IL-6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma.
Song L; Xu R; Cai W; Liang J; Cao N; Gao J; Tang X
Scand J Immunol; 2023 Jul; 98(1):e13271. PubMed ID: 38441314
[TBL] [Abstract][Full Text] [Related]
8. IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma.
Hu Z; Luo D; Wang D; Ma L; Zhao Y; Li L
Cell Physiol Biochem; 2017; 43(6):2379-2390. PubMed ID: 29073625
[TBL] [Abstract][Full Text] [Related]
9. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
10. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma.
Yin Z; Ma T; Lin Y; Lu X; Zhang C; Chen S; Jian Z
J Cell Biochem; 2018 Nov; 119(11):9419-9432. PubMed ID: 30015355
[TBL] [Abstract][Full Text] [Related]
11. Peri-tumor fibroblasts promote tumorigenesis and metastasis of hepatocellular carcinoma via Interleukin6/STAT3 signaling pathway.
Zhao Z; Xiong S; Wang R; Li Y; Wang X; Wang Y; Bai S; Chen W; Zhao Y; Cheng B
Cancer Manag Res; 2019; 11():2889-2901. PubMed ID: 31118769
[No Abstract] [Full Text] [Related]
12. Hepatocellular carcinoma-derived exosomal miRNA-761 regulates the tumor microenvironment by targeting the SOCS2/JAK2/STAT3 pathway.
Zhou XH; Xu H; Xu C; Yan YC; Zhang LS; Sun Q; Wang WL; Shi YJ
World J Emerg Med; 2022; 13(5):379-385. PubMed ID: 36119773
[TBL] [Abstract][Full Text] [Related]
13. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.
Liu Y; Liu A; Xu Z; Yu W; Wang H; Li C; Lin J
Apoptosis; 2011 May; 16(5):502-10. PubMed ID: 21311975
[TBL] [Abstract][Full Text] [Related]
14. Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion.
Yang J; Xing Z
Exp Biol Med (Maywood); 2021 Sep; 246(17):1928-1937. PubMed ID: 34053234
[TBL] [Abstract][Full Text] [Related]
15. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway.
Ni JS; Zheng H; Ou YL; Tao YP; Wang ZG; Song LH; Yan HL; Zhou WP
Surg Oncol; 2020 Sep; 34():113-120. PubMed ID: 32891315
[TBL] [Abstract][Full Text] [Related]
16. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells.
Zhang HY; Zhang Q; Zhang X; Yu C; Huo X; Cheng E; Wang DH; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G454-60. PubMed ID: 21148399
[TBL] [Abstract][Full Text] [Related]
17. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
Liu X; Zhang A; Xiang J; Lv Y; Zhang X
Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of protein disulfide‑isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma.
Kondo R; Ishino K; Wada R; Takata H; Peng WX; Kudo M; Kure S; Kaneya Y; Taniai N; Yoshida H; Naito Z
Int J Oncol; 2019 Apr; 54(4):1409-1421. PubMed ID: 30720090
[TBL] [Abstract][Full Text] [Related]
19. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.
Zhao Y; Wang J; Liu WN; Fong SY; Shuen TWH; Liu M; Harden S; Tan SY; Cheng JY; Tan WWS; Chan JKY; Chee CE; Lee GH; Toh HC; Lim SG; Wan Y; Chen Q
Hepatology; 2021 Sep; 74(3):1395-1410. PubMed ID: 33738839
[TBL] [Abstract][Full Text] [Related]
20. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma.
Mi F; Gong L
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28659496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
